EGFR inhibitors induced a restoring from mesenchymal to epithelial phenotype in TNBC cells and the EGFR TKIs erlotinib inhibited tumor growth and metastasis in a SUM149 xenograft mouse model, showing an antimetastatic effect that could be the basis of “overlap sensitivity” to dasatinib between M and BL2 subtypes [79]. This evidence concerns the gene EGFR and neoplasm.